The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

David S. Alberts

The University of Arizona Cancer Center

University of Arizona


AZ, USA. Electronic address:


Name/email consistency: high



  • The University of Arizona Cancer Center, University of Arizona, Tucson, AZ, USA. Electronic address:. 2012
  • University of Arizona Cancer Center, Tucson, AZ 85724-5024, USA. 1998 - 2008
  • Arizona Cancer Center, University of Arizona, Tucson, USA. 1997 - 2008
  • University of Arizona Cancer Center, 1515 North Campbell Avenue, PO Box 245024, Tucson, USA. 2004
  • The Arizona Cancer Center, Tucson, USA. 2004


  1. Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study. Alberts, D.S., Blessing, J.A., Landrum, L.M., Warshal, D.P., Martin, L.P., Rose, S.L., Bonebrake, A.J., Ramondetta, L.M. Gynecol. Oncol. (2012) [Pubmed]
  2. Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200). Alberts, D.S., Liu, P.Y., Wilczynski, S.P., Clouser, M.C., Lopez, A.M., Michelin, D.P., Lanzotti, V.J., Markman, M. Gynecol. Oncol. (2008) [Pubmed]
  3. Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival. Alberts, D.S., Marth, C., Alvarez, R.D., Johnson, G., Bidzinski, M., Kardatzke, D.R., Bradford, W.Z., Loutit, J., Kirn, D.H., Clouser, M.C., Markman, M. Gynecol. Oncol. (2008) [Pubmed]
  4. Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211). Alberts, D.S., Liu, P.Y., Wilczynski, S.P., Jang, A., Moon, J., Ward, J.H., Beck, J.T., Clouser, M., Markman, M. Int. J. Gynecol. Cancer (2007) [Pubmed]
  5. Karyometry of the colonic mucosa. Alberts, D.S., Einspahr, J.G., Krouse, R.S., Prasad, A., Ranger-Moore, J., Hamilton, P., Ismail, A., Lance, P., Goldschmid, S., Hess, L.M., Yozwiak, M., Bartels, H.G., Bartels, P.H. Cancer Epidemiol. Biomarkers Prev. (2007) [Pubmed]
  6. Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: An intergroup study. Alberts, D.S., Hannigan, E.V., Liu, P.Y., Jiang, C., Wilczynski, S., Copeland, L., Markman, M. Gynecol. Oncol. (2006) [Pubmed]
  7. Proceedings of a GOG workshop on intraperitoneal therapy for ovarian cancer. Alberts, D.S., Markman, M., Muggia, F., Ozols, R.F., Eldermire, E., Bookman, M.A., Chen, T., Curtin, J., Hess, L.M., Liebes, L., Young, R.C., Trimble, E. Gynecol. Oncol. (2006) [Pubmed]
  8. Maximizing the delivery of intraperitoneal therapy while minimizing drug toxicity and maintaining quality of life. Alberts, D.S., Delforge, A. Semin. Oncol. (2006) [Pubmed]
  9. Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. Alberts, D.S., Martínez, M.E., Hess, L.M., Einspahr, J.G., Green, S.B., Bhattacharyya, A.K., Guillen, J., Krutzsch, M., Batta, A.K., Salen, G., Fales, L., Koonce, K., Parish, D., Clouser, M., Roe, D., Lance, P. J. Natl. Cancer Inst. (2005) [Pubmed]
  10. Safety and efficacy of dose-intensive oral vitamin A in subjects with sun-damaged skin. Alberts, D., Ranger-Moore, J., Einspahr, J., Saboda, K., Bozzo, P., Liu, Y., Xu, X.C., Lotan, R., Warneke, J., Salasche, S., Stratton, S., Levine, N., Goldman, R., Islas, M., Duckett, L., Thompson, D., Bartels, P., Foote, J. Clin. Cancer Res. (2004) [Pubmed]
  11. Long-term follow-up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology Group. Alberts, D.S., Jiang, C., Liu, P.Y., Wilczynski, S., Markman, M., Rothenberg, M.L. Int. J. Gynecol. Cancer (2004) [Pubmed]
  12. Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials. Alberts, D.S., Muggia, F.M., Carmichael, J., Winer, E.P., Jahanzeb, M., Venook, A.P., Skubitz, K.M., Rivera, E., Sparano, J.A., DiBella, N.J., Stewart, S.J., Kavanagh, J.J., Gabizon, A.A. Semin. Oncol. (2004) [Pubmed]
  13. Fecal bile acid concentrations in a subpopulation of the wheat bran fiber colon polyp trial. Alberts, D.S., Einspahr, J.G., Earnest, D.L., Krutzsch, M.F., Lin, P., Hess, L.M., Heddens, D.K., Roe, D.J., Martínez, M.E., Salen, G., Batta, A.K. Cancer Epidemiol. Biomarkers Prev. (2003) [Pubmed]
  14. Phase I pharmacokinetic trial and correlative in vitro phase II tumor kinetic study of Apomine (SR-45023A), a novel oral biphosphonate anticancer drug. Alberts, D.S., Hallum, A.V., Stratton-Custis, M., Garcia, D.J., Gleason-Guzman, M., Salmon, S.E., Santabarbara, P., Niesor, E.J., Floret, S., Bentzen, C.L. Clin. Cancer Res. (2001) [Pubmed]
  15. Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians' Network. Alberts, D.S., Martínez, M.E., Roe, D.J., Guillén-Rodríguez, J.M., Marshall, J.R., van Leeuwen, J.B., Reid, M.E., Ritenbaugh, C., Vargas, P.A., Bhattacharyya, A.B., Earnest, D.L., Sampliner, R.E. N. Engl. J. Med. (2000) [Pubmed]
  16. Chemoprevention of human actinic keratoses by topical 2-(difluoromethyl)-dl-ornithine. Alberts, D.S., Dorr, R.T., Einspahr, J.G., Aickin, M., Saboda, K., Xu, M.J., Peng, Y.M., Goldman, R., Foote, J.A., Warneke, J.A., Salasche, S., Roe, D.J., Bowden, G.T. Cancer Epidemiol. Biomarkers Prev. (2000) [Pubmed]
  17. A unifying vision of cancer therapy for the 21st century. Alberts, D.S. J. Clin. Oncol. (1999) [Pubmed]
  18. New Perspectives on an Old Friend: Optimizing Carboplatin for the Treatment of Solid Tumors. Alberts, D.S., Dorr, R.T. Oncologist (1998) [Pubmed]
  19. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers. Alberts, D.S., Fanta, P.T., Running, K.L., Adair, L.P., Garcia, D.J., Liu-Stevens, R., Salmon, S.E. Cancer Chemother. Pharmacol. (1997) [Pubmed]
WikiGenes - Universities